Welcome
This survey asks about the use of new immunological therapies such as dupilumab or upadacitinib to treat atopic dermatitis (AD).
As current PBS restrictions only permit dermatologists and immunologists to prescribe these medications for AD, this survey is restricted to these specialists and registrars in these specialties.
If you are NOT a dermatologist, immunologist or registrar
in either specialty, this survey is not for you.
in either specialty, this survey is not for you.
The primary objective of this project is to understand your real world experience when prescribing these new immunological therapies to treat AD.
- It is anticipated that the Pharmaceutical Benefits Advisory Committee (PBAC) will find insights obtained from clinicians useful when considering future submissions for the inclusion of immunological therapies that treat AD on the Pharmaceutical Benefits Scheme (PBS).
- To enhance the value of this project to you, this activity has been CPD Home approved as a Self-Reflection activity
Deidentified and aggregated results may be reported in scientific meetings and academic journals. Any personal information will be removed from the data to ensure your privacy. A more complete explanatory statement is available here.
We estimate that this survey will take approximately 30 minutes to complete. At the end of the survey, we will provide instructions to claim CPD credit.
Thank you for your time.